INTRODUCTION
Genetic alterations including chromosomal translocation, promoter hypermethylation, somatic mutation and gene deletion are believed to play a key role in oncogenesis. Alterations of the 9p21 locus have been implicated in many types of cancer, indicating a role for the tumour suppressor genes CDKN2A (MTS1) and CDKN2B (MTS2), which encode for p16 INK4a /p14 ARF and p15 INK4b , respectively. 1 Loss of cell proliferation control and regulation of cell cycle are known to be critical to cancer development. 2 Both p16 INK4a and p15 INK4b specifically inhibit only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013 . bloodjournal.hematologylibrary.org From cyclin/CDK-4/6 complexes that block cell division during the G1/S phase of the cell cycle. 3 It has been reported that CDKN2A and CDKN2B are frequently inactivated in various haematological malignancies. 1, 4 Loss of heterozygosity (LOH) of chromosome arm 9p, including the CDKN2A locus, is one of the most frequent genetic events in childhood acute lymphoblastic leukaemia (ALL) suggesting inactivation of the second allele or, possibly, haplo-insufficiency. [5] [6] [7] [8] Haploinsufficiency of a tumour suppressor gene, e.g. CDKN2A, has been shown to be adequate to promote tumour progression. [9] [10] [11] Homozygous deletion of CDKN2A has been suggested as the dominant mechanism of its inactivation in leukaemogenesis. 12 However, the reported frequencies of both hetero-and homozygous deletions in childhood ALL vary, 9-27% and 6-33% in B-cell precursor (BCP) ALL and 7-18% and 30-83% in T-ALL, respectively. 13 Similarly, the frequency of hypermethylation of the CDKN2A promoter has been reported to vary from 0-40% in childhood ALL. [14] [15] [16] [17] [18] [19] Although mutations in exons 1 and 2 of CDKN2A have been described in childhood ALL, their incidence appears to be low, ranging from 0-7%. 12, [20] [21] [22] [23] [24] As reported data on CDKN2A alterations in childhood ALL are discrepant, it remains important to reveal the role of this gene in cancer development. In this study we have used mutation and methylation analyses as well as genomic technologies to elucidate the principal mode of CDKN2A inactivation in childhood ALL. Moreover, the use of array based comparative genomic hybridisation (aCGH) and single nucleotide polymorphism (SNP) microarray mapping has allowed the architecture of CDKN2A deletions in this disease to be characterised. Finally, extensive screening using fluorescence in situ hybridisation (FISH) has enabled the frequency of deletions to be accurately determined in biologically relevant subgroups. Genomic DNA was extracted from mononuclear cells after density gradient centrifugation using a commercial kit (QiAmp DNA Blood Kit, Qiagen, USA), according to the manufacturer's instructions.
MATERIALS AND METHODS

Mutation analysis
PCR amplification for each exon was performed in 50 µl volume assays containing 1 X PCR buffer, 200 µM of dNTP mix, 1.5-2.5 mM MgCl2, 0.2-0.4 µM of each primer, 1.25U of Amplitaq Gold polymerase and 100 ng of genomic DNA. In addition, a final concentration of 2.5% dimethyl sulfoxide (DMSO) was used in the exon 2 reaction mixture. Primer pairs for exon 1, 2 and 3 were previously described. 20, 26 PCR conditions for exon 1 and 2 consisted of initial denaturation at 95°C for 10 minutes, followed by 35 cycles of denaturation at 94°C for 30 seconds, annealing at 56°C for 30 seconds and extension at 72°C for 30 seconds. The final extension at 72°C was performed for 5 minutes. PCR amplification of exon 3 was carried out using Touchdown protocol consisting of initial denaturation at 95ºC for 10 minutes, followed by 14 cycles (20 sec denaturation at 94ºC, 1 min annealing at 65-58ºC with a decrease of 0.5°C every cycle and 1 min extension at 72ºC) and a further 20 cycles with annealing at 58ºC for 1 min. All PCR products were resolved on 2% agarose gels stained with ethidium bromide and visualized under UV transillumination only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From Mutation screening of all exons was performed using denaturing high performance liquid chromatography (dHPLC) (WAVE® Nucleic Acid Fragment Analysis System, Transgenomic, UK). All PCR products showing homoduplex profiles were spiked with approximately equimolar proportions of a product known to contain a wild-type CDKN2A fragment, and re-screened in order to differentiate between wildtype homozygote and homozygote variants. DNA from a melanoma cell line (MM384) kindly provided by Dr. Nicholas Hayward (Queensland Institute of Medical Research, Australia) and a myeloid leukaemia cell line (HL60), known to contain CDKN2A mutations were used as positive controls for exon 1a and 2, respectively. Heteroduplex profiles for MM384 and HL60 cell lines were detected after spiking consistent with their homozygous mutant status. All samples showing an altered dHPLC profile were directly sequenced or cloned and then sequenced using standard methods (Pinnacle Lab., Newcastle University, UK).
Methylation analysis
The methylation status of the CDKN2A promoter regions was assessed by methylation specific-PCR (MSP) analysis. DNA modification (bisulphite treatment) was conducted by using CpGenome DNA Modification Kit (Chemicon International, CA). A total of 250 ng DNA was treated according to the manufacturer's protocol. DNA from Raji and HL60 cell lines were used as controls for methylated and unmethylated CDKN2A, respectively, as previously described. 3 All bisulphite-treated DNA samples were amplified by using the primer sets specific for the unmethylated and methylated CDKN2A sequences (referred to as p16U and p16M respectively), as previously reported. 27 The final concentration of the reagents in the PCR mixture were 1 X PCR buffer, 200 µM dNTP mix, 1.5 mM MgCl2, 0.2 µM of each primer set for p16U and p16M, 1.25U of Amplitaq Gold polymerase and bisulphite-modified DNA (50 ng) in a final volume of 25 µl. PCR conditions were as follows: initial denaturation at 95ºC for 10 minutes, followed by 14 cycles (20 sec denaturation at 94ºC, 1 min annealing at 64-57ºC with a decrease of 0.5ºC every cycle and 1 min extension at 72ºC) and a further 32 cycles with annealing at 57ºC for 1 min. Each PCR product was directly loaded onto 1.8% agarose gel, 28 Array based comparative genomic hybridisation (aCGH) analysis aCGH was performed with array platforms constructed from either large-insert DNA clones or oligonucleotides, offering genome coverage at 1Mb and 6Kb intervals, respectively. For the large insert arrays, DNA samples were processed in a dye-swap combination and sex-matched with DNA extracted from phenotypically normal individuals (Promega, Southampton, UK) before hybridization to two commercially available systems (Spectral Genomics and IntegraGen, Genosystems, Paris, France), as previously reported. 29 For the oligonucleotide array, sample DNA was sex-matched to the same control DNA and hybridized to the 244K whole genome array (Agilent Technologies, Santa Clara, California, USA) according to manufacturer's instructions. 30 Scanning, grid placement, spot quality, data normalization, fluorescence quantification, postprocessing of the array image and data analysis were performed as previously described. 31, 32 Regions of copy number alteration (CNA), identified by the largeinsert array, were defined as a minimum of three adjacent clones simultaneously deviating beyond the threshold values in both dye-swap experiments and were positioned onto the human genome sequence using BlueFuse software 
Fluorescence in situ hybridization (FISH)
FISH analysis was performed on frozen cytospins and/or fixed cells from diagnostic bone marrow. Three commercial probes were used to detect CDKN2A deletions in leukaemic cells: LSI® p16 (9p21) SpectrumOrange™/CEP® 9 SpectrumGreen™ Probe (Vysis/Abbott Diagnostics, Maidenhead, UK); P16 Deletion Probe (Cytocell Technologies Ltd., Cambridge, UK); p16 (CDKN2A) specific probe (Qbiogene/MP Biomedicals, Cambridge, UK). Probe and slide preparation as well as hybridization and washing steps were performed according to the manufacturers' protocols.
An additional home-grown dual-colour, CDKN2A deletion probe (consisting of BAC RP11-149I2/70L8 and the chromosome 9 centromere probe pMR9A; all clones from Sanger Institute, Hinxton, UK) (Wessex Regional Genetics Laboratory, WRGL) was also used. These were grown and labelled for FISH as previously described. 33 The approximate size of the p16/CDKN2A probes are: Vysis -190kb; Cytocell101kb; Qbiogene -not available; WRGL -101kb. A minimum of 100 interphase cells were scored in each test. A signal pattern of two red and two green (2R2G) was considered to represent a normal cell. Loss of one signal corresponding to the test and retention of both signals for the control probe (i.e. 1R2G or 2R1G depending on the probe) was considered to represent a heterozygous deletion. A homozygous deletion was defined as loss of both test signals with retention of both control signals (i.e. 0R2G or 2R0G depending on the probe). The cut-off level defined to rule out a false positive result was calculated to be 5%. Therefore, only abnormal cell populations comprising more than 5% of analysed cells were included. Rare cases with two different deleted populations (one heterozygous and one homozygous) were classified as having a homozygous deletion. Cases with loss of a whole chromosome 9 were not classified as having a deletion. 
RESULTS
Mutation screening
Mutation screening of all three exons was successfully performed on 47 patients who were known to have retained (by FISH or SNPA) at least one CDKN2A allele.
Samples tested were from diagnosis (n=21), relapse (n=25) or both time points (n=1) ( Table 1) . Chromatography profiles generated from dHPLC were inspected to detect heteroduplexes which indicated the presence of mutations/polymorphisms. All aberrant profiles were confirmed by DNA sequencing analysis. A known SNP was detected in 15 (32%) patients; detected at diagnosis (n=4), relapse (n=10) or both time points (n=1). Nine (19%) patients had the 500C>G SNP in the 3'UTR of exon 3: 7 (15%) patients were CG heterozygotes while 2 (4%) were GG homozygotes. Three patients who were CG heterozygotes at nucleotide 500 also carried the A148T polymorphism in exon 2. Six (13%) patients had the 540C>T polymorphism in the 3'UTR of exon 3: 4 (9%) patients were CT heterozygotes while 2 (4%) were TT homozygotes. Only one patient (L5C) harboured a somatic mutation. This was detected in a relapse sample and involved a base substitution of C>T in exon 2 at nucleotide 247, which resulted in the amino acid tyrosine replacing histidine at codon 83 (H83Y). Although this relapse sample showed an aberrant profile after dHPLC, initially no mutation was detected by sequencing analysis. DNA from this patient was cloned and after resequencing the mutation was confirmed in 2/20 clones; suggesting that the quantity of mutant DNA was too low to be detected by first direct sequencing. We concluded that only a minority of the blast cells harboured this mutation which was detected by the sensitive dHPLC technique but not by direct sequencing, in agreement with a previous study. 34 This patient had a normal karyotype and did not show loss of CDKN2A by FISH. However, SNP array analysis (see below) revealed copy number neutral LOH from 9p21.1 to the telomere.
Methylation screening
MSP analysis was performed on a total of 99 patients who were known to have retained (by FISH or SNPA) at least one CDKN2A allele (Table 1) . Samples tested 
Genomic analyses
High density SNPA analyses were performed on 98 patients at diagnosis (n=78), relapse (n=12) or both time points (n=8) ( Table 1) . No abnormality of the short arm of chromosome 9 was detected in 73 (74%) patients whereas 25 (26%) patients harboured either a deletion (n=17) or CNN LOH (n=8) of 9p. The absence of a 9p deletion was confirmed in 27 patients by FISH (n=8), aCGH (n=11) or both techniques (n=8). SNPA revealed a deletion of 9p in 17 (17%) patients (Figure 1Ai- iii). Most of the deletions were terminal [n=11: del(9)(p12)x1, del(9)(p13.1)x1, del(9)(p13.2)x1, del(9)(p13.3)x4, del(9)(p21.2)x1 and del(9)(p21.3)x3] but interstitial deletions also occurred [n=6: del(9)(p21.2p21.3)x1, del(9)(p21.3p22.1)x2, del(9)(p21.3p22.3)x1, del(9)(p21.3p21.3)x2]. All the deletions were confirmed by FISH (n=10), aCGH (n=2) or both techniques (n=5). In addition to these deletions, SNPA revealed CNN LOH (also known as acquired isodisomy and uniparental disomy) in 8 (8%) patients at diagnosis (n=6) and relapse (n=2). The area of CNN LOH (Figure 1Aiv ) ranged from ~28Mb to the whole chromosome: 9p21.1->9pter (n=2), 9p13->9pter (n=1), 9q21->9pter (n=1) and whole chromosome 9 (n=4). None of these patients showed a CDKN2A deletion by FISH (n=7 tested) or promoter hypermethylation (n=8). However, one patient did harbour a H83Y mutation in exon 2 of CDKN2A (see above). A high hyperdiploid karyotype was detected in 5
of these 8 patients, including 3 of the 4 patients with whole chromosome 9 CNN LOH but 2 normal copies of chromosome 9 was seen by cytogenetics.
Cytogenetics failed or was normal in the remaining 3 patients.
A selected series of patients (n=105) were analysed using aCGH at diagnosis (n=102), relapse (n=2) or both time points (n=1) (Table 1, Figure 1B The mean size of the larger deletion was 23.3Mb whereas the smaller deletion was more focal with a mean size of 1.4Mb: 7/15 biallelic deletions were less than 1Mb.
Correlation of CDKN2A deletions with demographic and cytogenetic features
In order to assess the true incidence of CDKN2A deletions in childhood ALL as a whole and within relevant biological subgroups, an extensive interphase FISH screening programme was carried out. Three independent and unbiased cohorts were identified as follows: 864 diagnostic samples from patients with BCP-ALL; 266 diagnostic samples from patients with T-ALL; and a relapse cohort comprising 69 BCP-ALL and 8 T-ALL patients. A total of 1,207 samples were screened with one of four FISH probes: Vysis, Cytocell, Qbiogene and WRGL (see methods and Table 1 ).
However, the majority of samples (96%) were tested with either the Vysis probe (n=515), WRGL probe (n=870) or both (n=216). Among 226 samples tested with more than one FISH probe, only 11 (<5%) cases showed discrepant results. In 4 cases the WRGL probe detected a biallelic deletion where the Vysis probe had only.
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Conventional cytogenetics was attempted on virtually all these samples (1197/1207, 99%) and was of sufficient quality to assess 9p status in 884 (73%). A cytogenetically visible 9p deletion/abnormality was detected in 133/277 (48%) samples where FISH detected a deletion. In a small number of samples (n=19) a cytogenetically visible 9p abnormality did not correlate with a deletion of
CDKN2A.
The incidence of CDKN2A deletions and the proportion of biallelic deletions present at diagnosis were higher in T-ALL patients compared to BCP-ALL patients: 50% v 21% (p<0.001) & 62% v 43% (p=0.001), respectively ( Table 2 ). Among BCP-ALL patients, CDKN2A deletions were more prevalent among older children (10+ years, p<0.001) and those with a white cell count (WCC) of greater than 50x10 9 /L (p<0.001). However, this was not the situation among T-ALL patients (Table 2) .
Moreover, within the BCP-ALL and T-ALL cohorts the incidence of CDKN2A deletions was associated with specific cytogenetic subgroups. The incidence of deletions was significantly lower among BCP-ALL patients with the ETV6-RUNX1 fusion or high hyperdiploidy, whereas it was significantly higher among patients with t(9;22)(q34;q11) or t(1;19)(q23;p13) ( Table 2 ). Among T-ALL patients, those with involvement of TLX1 or TLX3 had significantly higher rates of deletion when compared with T-ALL patients without these abnormalities (Table 2) . Considering BCP-ALL and T-ALL patients together, CDKN2A deletions were rare among those with MLL translocations [4/33 (12%) v 285/1012 (28%), p<0.05]. However, the difference was not significant when BCP-ALL and T-ALL patients were considered separately ( Table 2) . Among 10 patients with t(4;11)(q21;q23) only one had a homozygous deletion of CDKN2A and none of the 9 patients with t(11;19)(q23;p13) harboured a deletion. Despite the incidence of CDKN2A deletions varying markedly by immunophenotype, age, WCC and cytogenetic subgroup, the only.
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The incidence of CDKN2A deletions at relapse was slightly higher than that seen at diagnosis among BCP-ALL patients, although the difference was not statistically significantly: 21/69 (30%) v 180/864 (21%) p=0.06. The relapse cohort comprised only 8 T-ALL patients of which only 2 (25%) harboured a CDKN2A deletion, however both were biallelic. Among 44 patients where we were able to assess CDKN2A status at both diagnosis and relapse by FISH, SNPA or aCGH, 28 (64%) patients had normal CDKN2A at both time points. The remaining 16 (36%) patients showed retention (n=9, 20%) or gain (n=7, 16%) of a CDKN2A deletion or 9p CNN LOH between diagnosis and relapse. The 7 CDKN2A abnormalities acquired at relapse comprised: 2 monoallelic deletions, 4 biallelic deletions and 1 CNN LOH between 9p21.1 and the telomere. These 7 patients did not have any remarkable features with respect to age at diagnosis, WCC, immunophenotype, karyotype or time to relapse (data not shown). Interestingly, 6 (86%) of these patients were male and three relapses involved the testes as well as the bone marrow.
DISCUSSION
This is the first study to utilise five separate technologies to assess the principal mode of CDKN2A inactivation in childhood ALL. We found that CDKN2A mutations were rare in this disease which agrees with most [21] [22] [23] [24] but not all previous studies. 12, 20 We found only one mutation which was a C to T substitution in exon 2 that produced an amino acid change from histidine to tyrosine at codon 83 (H83Y) and has been shown to be defective in inducing cell cycle arrest. 35 This H83Y mutation has not previously been reported in leukaemia but has been detected in bladder and gastrointestinal stromal tumors. 36, 37 Despite screening over 100 samples for hypermethylation of the CDKN2A promoter, we found partial methylation in only one diagnostic sample. Two previous studies of a similar size only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From found CDKN2A methylation in 7% 16 and 32% 18 . Several much smaller studies (<30 patients) have reported equally variable levels of methylation. However, it has been suggested recently that CDKN2A hypermethylation is not a disease specific event since it has been observed in the mononuclear cells from normal individuals. 38 In contrast, we have demonstrated that genomic deletion of CDKN2A is substantially more prevalent in childhood ALL (20% in BCP-ALL and 50% in T-ALL) than either mutation or methylation. As the cohorts we screened for mutation and methylation excluded cases with biallelic deletion of CDKN2A our figures are under-estimates of the true incidence. We assessed genomic deletion by SNPA, aCGH and FISH and found a very high degree of concordance between the three techniques with only a handful of deletions detected by aCGH which were below the resolution of FISH. The apparent difference in detection rate between SNPA (17%) and aCGH (32%) is due to the fact that specific cytogenetic subgroups were selected for aCGH analysis. Therefore, we concluded that genomic deletion is the principal mode of CDKN2A inactivation in childhood ALL and that FISH is a reliable and accurate method for detecting these deletions.
In order to accurately assess the incidence of mono-and biallelic deletions in childhood ALL, we screened two large and unbiased cohorts of BCP-ALL and T-ALL patients by FISH. Over 200 patients were screened with more than one FISH probe and there was a high degree of concordance. As expected the smaller home grown WRGL probe detected a handful of smaller deletions that were below the resolution of the commercial probes. Despite these discrepancies and those detected when comparing aCGH and FISH, the numbers of patients involved were small and not sufficient to affect the subsequent analyses. In agreement with previous large studies, 13, 39, 40 we found that the incidence of CDKN2A deletions was significantly higher among T-ALL patients compared with BCP-ALL patients which included the proportion of biallelic deletions. Among BCP-ALL patients, we found a frequency of CDKN2A deletions of 21% which was the same as Kawamata et al 41 41 (78%). These differences are probably due to variation in the underlying patient cohort with respect to age and WCC rather than due to the technique employed. Firstly, evidence from our study and Usvasalo et al 40 indicated that the vast majority of CDKN2A deletions are detectable by FISH. Secondly, data from this study and Mirebeau et al 42 showed that the frequency of CDKN2A deletions varied according to age and presenting WCC. Our study included over 1,200 patients (more than the combined total from the three main previous studies), thereby minimising the effect of any slight variations in age or WCC distribution.
The number of cases included in our study was sufficiently large to systematically address the relationship between CDKN2A deletions and specific cytogenetic subgroups. CDKN2A deletions were less frequent in patients with high hyperdiploidy and the ETV6-RUNX1 fusion compared to those without these abnormalities. We found a similar incidence of deletions among high hyperdiploidy patients as Mirebeau et al 42 , but these authors found that over a third of ETV6-RUNX1 patients had a deletion. However their result was based on fewer than 50 patients, whereas over 200 ETV6-RUNX1 positive patients were included in this study. In addition, we observed a higher incidence of CDKN2A deletions among patients with t(1;19) and t (9;22) . Although patients with a MLL translocation were divided between the BCP-ALL and T-ALL cohorts, it was clear that the incidence of CDKN2A deletions was rare in this subgroup with only 4/33 (12%) showing evidence of a deletion. Interestingly the incidence also varied within the T-ALL cohort where patients with TLX3 or TLX1 rearrangements had a high incidence of deletion. In a separate study, we have recently observed a strong correlation between the presence of t(6;14)(p22;q32)/IGH@-ID4 and a monoallelic CDKN2A deletion. 43 As in previous studies, we observed both monoallelic and biallelic CDKN2A deletions and found that the latter were more prevalent in T-ALL. 13, 40, 42 only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From Interestingly, within the BCP-ALL and T-ALL cohorts the proportion of biallelic deletions did not vary by age, WCC or cytogenetic subgroup, with the exception of t(9;22) and normal karyotypes. However these observations were based on relatively few cases. In our cohort, biallelic deletions comprised one large and one much smaller deletion. A recent aCGH/FISH study by Usvasalo 40 , which focussed on older children and adolescents, observed a similar architecture.
The use of SNP arrays allowed the identification of CNN LOH, a phenomenon which has recently been associated with malignancy, including ALL. 41, [44] [45] [46] Previous studies have shown that this genetic mechanism is associated with the presence of homozygous mutations: JAK2 in myeloproliferative diseases, PTCH in basal cell carcinomas and FLT3 in AML. 44, 47, 48 None of our CDKN2A CNN LOH cases were associated with deletion or methylation and only one had a CDKN2A mutation.
However, the region of CNN LOH always encompassed numerous other genes and in half of the cases extended to the whole chromosome; indicating the likely involvement of other candidate genes such as PAX5 at 9p13.2. 39 Recently, Kawamata et al 41 identified a similar incidence of 9p / whole chromosome 9 CNN LOH (12%) among children with ALL. However, Kawamata et al found an association between 9p CNN LOH and CDKN2A deletion but not with whole chromosome 9 CNN LOH. Interesting both studies showed a strong association between 9p CNN LOH and high hyperdiploidy and this was particularly strong for cases with whole chromosome 9 CNN LOH. Therefore, it is not surprising that chromosome 9 is rarely gained in children with high hyperdiploidy. 49 The literature is divided as to the prognostic relevance of CDKN2A deletions in childhood ALL with some studies indicating an adverse effect [50] [51] [52] [53] [54] while others show no effect. 42, 55, 56 These studies followed several cytogenetic based reports which suggested an adverse outcome for patients with a cytogenetically visible 9p abnormality. 57, 58 The majority of patients in this study are being treated on an ongoing clinical trial, hence we are unable to present survival analysis. However, our results are highly relevant to this debate on prognosis. We have demonstrated only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From unequivocally that the frequency of CDKN2A deletions is unevenly distributed across distinct cytogenetic subgroups and therefore any study assessing their prognostic impact must incorporate analysis stratified by cytogenetics. It is possible that the inconsistent results of previous studies with respect to the prognostic relevance of CDKN2A deletions are due to the variable frequency of deletions by cytogenetic subgroup. However, it is also possible that CDKN2A deletions do not represent a true independent prognostic factor. A large study incorporating cytogenetics and the accurate determination of CDKN2A deletion is required to address this important issue. We did not observe any difference in the incidence of CDKN2A deletion between diagnosis and relapse but given the small number of patients in our series a larger study will be required to definitely answer this question. However, we would not draw the same conclusion for T-ALL where the frequency of CDKN2A deletions is higher, less variable by genetic subtype and the subject of fewer analyses.
In conclusion we have demonstrated that the principal mode of CDKN2A inactivation in childhood ALL is by genomic deletion and that FISH is an efficient detection method. Moreover, we have established that the frequency of deletions varies considerably by genetic subtype, especially within BCP-ALL where this variation is likely to account for discrepant reports as to its prognostic relevance. The architecture of biallelic deletions and the observation of large areas of 9p with disease specific CNN LOH implicate other genes within this region which are likely to be important, both for maintaining and initiating the leukemia phenotype. only. 
